BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• 

  Drug Development

  Amylyx and ALS Researchers Look to Build on Relyvrio Momentum (Updated)

  The FDA’s approval of Amylyx’s Relyvrio has ignited the growing momentum in the ALS space. BioSpace spoke with Amylyx co-CEOs Justin Klee and Josh Cohen and leading ALS researcher Dr. Merit Cudkowicz.

  October 3, 2022

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Business

  Q3 2022: Layoffs Continue, Alzheimer’s Soars and Accelerated Approvals Fall

  The third quarter of 2022 saw continued job cuts, a shift in focus away from COVID-19, an unexpected boost in the Alzheimer’s research space and increased scrutiny of accelerated approvals.

  October 3, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Clene’s ALS Add-On Misses Mark in HEALEY Trial

  Clene’s gold nanocrystal asset CNM-Au8 failed to hit the primary endpoint in the HEALEY ALS trial, but strong survival signals at six months warrant additional exploration in treating ALS.

  October 3, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Deals

  M&A Frenzy: Incyte & Villaris, AmplifyBio & PACT, Estrella Earns Nasdaq Listing (Updated)

  Incyte Corporation will acquire privately-held Villaris and AmplifyBio will acquire PACT Pharma, while Estrella will gain a spot on the Nasdaq Exchange.

  October 3, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  AstraZeneca Acquires LogicBio for $68 Million to Bolster Genomics Pipeline

  AstraZeneca is acquiring LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts to braoden its portfolio in genomics and rare diseases.

  October 3, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Synlogic’s CSO Outlines Risks and Opportunities in Emerging Synthetic Biotics Space

  Synlogic, Senti Biosciences and Novome are pioneering the field of synthetic biotics, which is so new there are only a handful of scientific articles using either that term or ‘engineered living therapeutics.

  October 3, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Deals

  Myovant Turns Down Acquisition Offer from Largest Stakeholder

  Myovant Sciences formed a special committee of independent directors to assess Sumitovant Biopharma’s offer after Sumitovant announced plans to acquire the company.

  October 3, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  AAO 2022: Janssen, REGENXBIO, Apellis and More

  Gene therapies developed by Janssen, Atsena, REGENXBIO and AbbVie showed promise against eye diseases this weekend at the American Academy of Ophthalmology 2022 meeting.

  October 3, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Intercept Strikes Out in Phase III NASH Trial

  Intercept Pharmaceuticals’ Ocaliva failed to treat patients with compensated cirrhosis due to nonalcoholic steatohepatitis better than a placebo in a Phase III trial, the company announced Friday.

  October 3, 2022

   · 

  1 min read

   · 

  Paul Elias
• 

  Drug Development

  Clinical Catch-Up: Scandion Oncology, Edesa Biotech, Clovis & More

  Scandion Oncology, Edesa, Clovis, Lexicon and Cytokinetics share a string of positive news from their clinical trials on heart failure, cancer, COVID-19 and ARDS.

  October 3, 2022

   · 

  5 min read

   · 

  Vanessa Doctor, RN